Celonic launches stand-alone GMP analytics portfolio
Challenging positions in upstream processing
Celonic is specialized in the production of recombinant proteins in eukaryotic expression systems in all development stages e.g. proof-of-concept studies (research), preclinical (non-GMP) and clinical studies (GMP). Besides, Celonic offers solutions for a complete process development of biopharmaceuticals.
- Production of e.g. antibodies, fusion proteins, cytokines, biosimilars …
- Production in each scale up to market demands
- Procedures for the cultivation of adherent and suspension cells
- Experience in the cultivation of a large number of eukaryotic cells e.g. CHO, HEK293, HeLa, NS0, NS1, SP2.0, ...
- Cultivation in different types of bioreactor systems: Wave-bioreactor (20, 50, 1'000 liters) and stirred vessel (up to 1'000 liters single use)
All of these cultivation systems may be operated in batch and fed-batch mode to achieve the optimal space/time yield for each process.
> Upstream Processing
Subsequent product purifications are achieved in our seperate downstream process area.
> Downstream Processing
The GMP production is completely performed in our Basel facility certified by SwissMedic for the production of biopharmaceuticals for clinical studies and market supply.
> Basel Facility
Under non-GMP conditions, we apply all established fermentation systems (stirred vessel, wave bioreactor). They enable the cultivation of animal or human cells under optimal conditions. The choice is dependent on our customers’ preferences. All systems are combined with process control units that allow the cultivation of animal and human cells under optimal conditions. Due to the high space-time yield of continuously operated processes Celonic is poised to produce monoclonal antibodies and recombinant proteins quickly and cost effective.
Celonic offers individual, customer specific solutions for the production of recombinant proteins, starting at proof-of concept experiments. We provide solutions on flexible production platforms:
- Production processes adapted to the needs and specific productivity of the particular cell line
- Production of sufficient amounts of recombinant proteins even from low-producer cell lines benefitting from advances of high cell density by using specific techniques
Key words: Cellonic, Contract Manufacturing Organization, Contract Analytic, Contract Research, Cell line development, stable high producer cell line, high producing cell line, regulatory conform, expression optimization, culture process optimization, USP, DSP, upstream process development, downstream process development, GMP, cGMP, non-GMP, GMP-like, GLP, GCP, manufacturing, GMP manufacturing license, animal tox study material, toxicology, biologic material, recombinant monoclonal antibody, recombinant protein, mammalian cell lines, cells, CHO, fast track cell line development, pre-clinical, clinical study material, market supply manufacturing, scale-up development, stainless steel stirred tank bioreactors, wave bioreactor, 1000 L scale, 300 L scale, serum free media, chemically defined media, cell culture media, transfection in serum free media, vector construction, mini pools, stability testing, MCB, Master Cell Bank, WCB, Working Cell Bank, PSB, Primary Seed Bank, research cell bank, Quality Control, HPLC for biologics, Protein A HPLC, parallel culturing systems, virus inactivation, validation batches, lots, downscale model, virus validation study, reference standard, pilot production, Drug Substance, Drug Product, specific Host Cell Protein assay, HCP, quality strategy, GLP-analytics, CHO K1, DG44, DHFR, biopharmaceuticals, HELA, HEK293, animal cells, CEMAX, SEFEX, biosimilar, biotechnology, EMA, EMEA, FDA, IgG, proof of concept, cultivation, suspension, adherent, cell growth, regulatory affairs, quality management, quality assurance, Wave bioreactors, immune therapeutics, cancer therapeutics, pharmaco kinetic, dynamic, large scale manufacturing, feeding strategy, dissolved oxygen, glucose level, human like glycosylation structure, glycosylation optimisation, affinity, dimerization, aggregates formation, Q-sepharose, Heparin sepharose, ion exchange, anionic cationic chromatography, dialysis, tangential flow filtration, TFF, ultra-filtration, nano-filtration, virus-filtration, sterile filtration, Bioburden reduction, API formulation, formulation buffer study, amplification, cloning, sub-cloning, shaker flasks, spinner culture, 6-well-culture, fed-batch, perfusion, disposable bioreactors, affinity chromatography, cleaning validation, WFI, harvest, primary clone, documentation, SOP, instruction, Master Batch Record, quality management handbook, clean rooms, class C, 2-8°C, room temperature, column chromatography, biosimilars, avastin, herceptin